5.05 USD
+0.25 (+5.21%)
5.1 USD
+0.05 (+0.99%)
We assign a fundamental rating of 2 out of 10 to EVAX. EVAX was compared to 530 industry peers in the Biotechnology industry. EVAX has a bad profitability rating. Also its financial health evaluation is rather negative. EVAX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EVAX had negative earnings in the past year.
EVAX had a negative operating cash flow in the past year.
In the past 5 years EVAX always reported negative net income.
EVAX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -53.35%, EVAX is in line with its industry, outperforming 46.60% of the companies in the same industry.
The Return On Equity of EVAX (-192.35%) is worse than 66.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.35% | ||
| ROE | -192.35% | ||
| ROIC | N/A |
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for EVAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVAX has been increased compared to 1 year ago.
EVAX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVAX has an improved debt to assets ratio.
2.2 Solvency
EVAX has an Altman-Z score of -0.17. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.17, EVAX is in line with its industry, outperforming 60.00% of the companies in the same industry.
EVAX has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
EVAX has a Debt to Equity ratio of 1.73. This is in the lower half of the industry: EVAX underperforms 77.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.17 |
ROIC/WACCN/A
WACC5.64%
2.3 Liquidity
A Current Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.
EVAX has a Current ratio (3.42) which is in line with its industry peers.
A Quick Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.
EVAX has a Quick ratio (3.42) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.07% over the past year.
Looking at the last year, EVAX shows a very strong growth in Revenue. The Revenue has grown by 132.20%.
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105%
Revenue 1Y (TTM)132.2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%148.33%
3.2 Future
EVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.29% yearly.
Based on estimates for the next years, EVAX will show a very strong growth in Revenue. The Revenue will grow by 40.90% on average per year.
EPS Next Y85.61%
EPS Next 2Y32.17%
EPS Next 3Y25.84%
EPS Next 5Y15.29%
Revenue Next Year14.66%
Revenue Next 2Y-56.29%
Revenue Next 3Y-25.99%
Revenue Next 5Y40.9%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVAX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EVAX's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.17%
EPS Next 3Y25.84%
5. Dividend
5.1 Amount
EVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.05
+0.25 (+5.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.48%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap40.02M
Revenue(TTM)7.65M
Net Income(TTM)-11.98M
Analysts82.22
Price Target12.58 (149.11%)
Short Float %1.94%
Short Ratio0.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.81%
Min EPS beat(2)24.59%
Max EPS beat(2)97.03%
EPS beat(4)4
Avg EPS beat(4)54.87%
Min EPS beat(4)11.56%
Max EPS beat(4)97.03%
EPS beat(8)7
Avg EPS beat(8)54.84%
EPS beat(12)10
Avg EPS beat(12)37.39%
EPS beat(16)13
Avg EPS beat(16)31.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)159.7%
EPS NY rev (1m)40.15%
EPS NY rev (3m)85.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)491.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.43 | ||
| P/tB | 6.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.01
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.4
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.35% | ||
| ROE | -192.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 | ||
| Altman-Z | -0.17 |
F-Score6
WACC5.64%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105%
EPS Next Y85.61%
EPS Next 2Y32.17%
EPS Next 3Y25.84%
EPS Next 5Y15.29%
Revenue 1Y (TTM)132.2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%148.33%
Revenue Next Year14.66%
Revenue Next 2Y-56.29%
Revenue Next 3Y-25.99%
Revenue Next 5Y40.9%
EBIT growth 1Y26.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.7%
OCF growth 3YN/A
OCF growth 5YN/A
EVAXION A/S / EVAX FAQ
Can you provide the ChartMill fundamental rating for EVAXION A/S?
ChartMill assigns a fundamental rating of 2 / 10 to EVAX.
Can you provide the valuation status for EVAXION A/S?
ChartMill assigns a valuation rating of 1 / 10 to EVAXION A/S (EVAX). This can be considered as Overvalued.
How profitable is EVAXION A/S (EVAX) stock?
EVAXION A/S (EVAX) has a profitability rating of 0 / 10.
What is the expected EPS growth for EVAXION A/S (EVAX) stock?
The Earnings per Share (EPS) of EVAXION A/S (EVAX) is expected to grow by 85.61% in the next year.